• Publications
  • Influence
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
TLDR
This work has shown that the CXCL12/CXCR4 axis is involved in tumor progression, angiogenesis, metastasis, and survival, and this pathway is a target for therapeutics that can block the CZC receptor 4 interaction or inhibit downstream intracellular signaling. Expand
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
TLDR
BMN 673 is the most potent clinical PARP inhibitor tested to date with the highest efficiency at trapping PARP–DNA complexes and is also approximately 100-fold more cytotoxic than olaparib and rucaparIB in combination with the DNA alkylating agents methyl methane sulfonate and temozolomide. Expand
Tumor Evasion of the Immune System by Converting CD4+CD25− T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-β
TLDR
It is demonstrated that tumor cells directly convert CD4+CD25− T cells to Treg cells through production of high levels of TGF-β, suggesting a possible mechanism through which tumor cells evade the immune system. Expand
Antibody Conjugate Therapeutics: Challenges and Potential
TLDR
The time may have come for antibody conjugates to become a major contributor to improving treatment for cancer patients. Expand
Overexpression of metallothionein confers resistance to anticancer drugs.
TLDR
Tumor cell lines with acquired resistance to the antineoplastic agent cis-diamminedichloroplatinum(II) overexpressed metallothionein and demonstrated cross-resistance to alkylating agents such as chlorambucil and melphalan. Expand
Vascular gene expression in nonneoplastic and malignant brain.
TLDR
A cell-specific transcriptome analysis from surgically harvested nonneoplastic and tumor-associated endothelial cells reveals distinct gene expression patterns and consistent up-regulation of certain glioma endothelial marker genes across patient samples, and defines the G-protein-coupled receptor RDC1 as a tumor endothelium marker whose expression is distinctly induced in tumor endothelial Cells of both brain and peripheral vasculature. Expand
Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).
TLDR
The mechanism of resistance of the SCC-25/CP cell line to CDDP is multifactorial, involving plasma membrane changes, increased cytosolic binding, and decreased DNA cross-linking. Expand
The proteasome inhibitor PS-341 in cancer therapy.
TLDR
The anticancer activity of the boronic acid dipeptide proteasome inhibitor PS-341 was examined in vitro and in vivo, and it seemed to produce primarily additive tumor growth delays against the s.c. tumor. Expand
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
TLDR
SLFN11 is a relevant predictive biomarker of sensitivity to PARP inhibitor monotherapy in SCLC and combinatorial therapy with TMZ is identified as a particularly promising therapeutic strategy that warrants further clinical investigation. Expand
Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.
TLDR
Agents targeting nuclear kinases appear to be effective in SCLC lines, and Associating drug response with micro-RNA expression indicated that lines most sensitive to etoposide and topotecan expressed high miR-200c-3p and lowMiR-140-5p and miR -9- 5p, while the BCL-2/BCL-XL inhibitors produced similar response patterns. Expand
...
1
2
3
4
5
...